Track topics on Twitter Track topics that are important to you
3275 Corporate View
United States of America
* Prana Biotechnology Ltd - further advice from US Food and Drug Administration (FDA) on steps necessary to remove Partial Clinical Hold (PCH) on PBT2
Prana Biotechnology Ltd. shares rose 9.9% during mid-day trading on Friday . The company traded as high as $5.39 and last traded at $5.23, with a volume of 231,103 shares trading hands.
Shares of Prana Biotechnology Ltd. have been given a consensus broker rating score of 3.00 from the one analysts that provide coverage for the company, Zacks Investment Research reports. One research ...
* Asx alert-prana announces $4.8 million research and development refund-pbt.ax
SummaryPrana Biotechnology Ltd Prana Biotech is a pharmaceutical company that develops therapeutic drugs. The company is conducting research into Huntington disease, Alzheimer's disease, brain cancer,...
Prana Biotechnology was established to commercialise research into Alzheimer's disease and other major age-related neurodegenerative disorders. The Company was incorporated in 1997 and listed on the A...
Prana Biotechnology has developed a proprietary library of class-leading chemical compounds. This library is combined with a drug development program to explore novel therapeutics in multiple disease ...
We have published hundreds of Prana news stories on BioPortfolio along with dozens of Prana Clinical Trials and PubMed Articles about Prana for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Prana Companies in our database. You can also find out about relevant Prana Drugs and Medications on this site too.